Combioxin Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 3

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 3

Combioxin General Information

Description

Developer of innovative anti-virulence drugs designed to treat severe bacterial infections and combat antibiotic resistance. The company's therapeutic approach consists of using liposomes engineered to neutralize virulence effectors, enabling to restore health in critically ill patients suffering from severe bacterial pneumonia.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Corporate Office
  • Route de la corniche 8
  • 1066 Epalinges
  • Switzerland
+41 021
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Route de la corniche 8
  • 1066 Epalinges
  • Switzerland
+41 021

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Combioxin Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Accelerator/Incubator 01-Jul-2022 Completed Clinical Trials - General
2. Accelerator/Incubator 17-May-2019 Completed Startup
1. University Spin-Out 01-Jan-2015 Completed Startup
To view Combioxin’s complete valuation and funding history, request access »

Combioxin Patents

Combioxin Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210259967-A1 Treatment of sepsis and septic shock Inactive 20-Apr-2018
CA-3097045-A1 Treatment of sepsis and septic shock Pending 20-Apr-2018
AU-2019254640-A1 Treatment of sepsis and septic shock Active 20-Apr-2018
EP-3781210-A1 Treatment of sepsis and septic shock Active 20-Apr-2018
JP-2024099554-A Treatment of sepsis and septic shock Pending 20-Apr-2018 A61K9/127
To view Combioxin’s complete patent history, request access »

Combioxin Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Combioxin Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Fongit Accelerator/Incubator Minority
MassChallenge Accelerator/Incubator
University of Bern University
To view Combioxin’s complete investors history, request access »

Combioxin FAQs

  • When was Combioxin founded?

    Combioxin was founded in 2015.

  • Where is Combioxin headquartered?

    Combioxin is headquartered in Epalinges, Switzerland.

  • What is the size of Combioxin?

    Combioxin has 3 total employees.

  • What industry is Combioxin in?

    Combioxin’s primary industry is Drug Discovery.

  • Is Combioxin a private or public company?

    Combioxin is a Private company.

  • What is Combioxin’s current revenue?

    The current revenue for Combioxin is .

  • Who are Combioxin’s investors?

    Fongit, MassChallenge, and University of Bern have invested in Combioxin.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »